Emcure Pharmaceuticals reported steady but slower domestic growth in FY26, with India sales rising 10% YoY to ₹4,027 crore.
The company said growth was led by cardiac, CNS and oncology segments, along with consolidation of domestic operations and portfolio expansion via partnerships.
However, domestic performance lagged international markets, which grew at over 22% during the year.
Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “In FY26, the first year of our five-year strategic plan, Emcure delivered strong financial performance with over US$1 billion in revenue and 16.6% growth. International markets demonstrated robust momentum while our domestic business recorded steady growth. We delivered ~41% adjusted PAT growth in the year. We strategically expanded through in-licensing, Zuventus minority buyout and bolt-on acquisitions in the UK and Canada. Our R&D pipeline in complex injectables and biosimilars remains a key driver of future value. Our priorities remain clear – to deliver sustainable, above-industry growth and consistent margin expansion, while continuing to build sustainable long-term value for all stakeholders.”
